GENINUS Past Earnings Performance
Past criteria checks 0/6
GENINUS's earnings have been declining at an average annual rate of -21.6%, while the Biotechs industry saw earnings growing at 2.7% annually. Revenues have been declining at an average rate of 3.1% per year.
Key information
-21.6%
Earnings growth rate
-19.8%
EPS growth rate
| Biotechs Industry Growth | 11.7% |
| Revenue growth rate | -3.1% |
| Return on equity | -46.6% |
| Net Margin | -180.0% |
| Last Earnings Update | 30 Sep 2024 |
Recent past performance updates
Revenue & Expenses Breakdown
How GENINUS makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 24 | 6,705 | -12,068 | 8,678 | 1,729 |
| 30 Jun 24 | 6,404 | -12,653 | 8,815 | 2,177 |
| 31 Mar 24 | 6,831 | -10,139 | 7,925 | 1,495 |
| 31 Dec 23 | 6,967 | -9,684 | 7,079 | 2,203 |
| 30 Sep 23 | 6,923 | -9,922 | 5,672 | 3,375 |
| 31 Dec 22 | 10,083 | -9,385 | 4,659 | 5,327 |
Quality Earnings: A389030 is currently unprofitable.
Growing Profit Margin: A389030 is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: Unable to establish if A389030's year-on-year earnings growth rate was positive over the past 5 years as it has been trading publicly for less than 3 years.
Accelerating Growth: Unable to compare A389030's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: A389030 is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (5.8%).
Return on Equity
High ROE: A389030 has a negative Return on Equity (-46.56%), as it is currently unprofitable.